Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
KALVISTA PHARMACEUTICALS INC (KALV) Stock Price & Overview
NASDAQ:KALV • US4834971032
Current stock price
26.67 USD
+7.43 (+38.62%)
At close:
26.63 USD
-0.04 (-0.15%)
After Hours:
The current stock price of KALV is 26.67 USD. Today KALV is up by 38.62%. In the past month the price increased by 32.49%. In the past year, price increased by 96.83%.
KALV Key Statistics
52-Week Range9.83 - 26.76
Current KALV stock price positioned within its 52-week range.
1-Month Range18.66 - 26.76
Current KALV stock price positioned within its 1-month range.
- Market Cap
- 1.366B
- P/E
- N/A
- Fwd P/E
- 30.76
- EPS (TTM)
- -1.90
- Dividend Yield
- N/A
KALV Stock Performance
Today
+38.62%
1 Week
+36.35%
1 Month
+32.49%
3 Months
+70.85%
Longer-term
6 Months +144.46%
1 Year +96.83%
2 Years +134.98%
3 Years +212.66%
5 Years +6.81%
10 Years N/A
KALV Stock Chart
KALV Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KALV. When comparing the yearly performance of all stocks, KALV is one of the better performing stocks in the market, outperforming 95.13% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
KALV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KALV. KALV may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
KALV Earnings
On March 25, 2026 KALV reported an EPS of -0.92 and a revenue of 13.69M. The company missed EPS expectations (-188.63% surprise) and missed revenue expectations (-71.72% surprise).
Next Earnings DateN/A
Last Earnings DateMar 25, 2026
PeriodQ2 / 2026
EPS Reported-$0.92
Revenue Reported13.692M
EPS Surprise -188.63%
Revenue Surprise -71.72%
KALV Forecast & Estimates
15 analysts have analysed KALV and the average price target is 35.02 USD. This implies a price increase of 31.31% is expected in the next year compared to the current price of 26.67.
Analysts
Analysts86.67
Price Target35.02 (31.31%)
EPS Next Y33.67%
Revenue Next YearN/A
KALV Index Membership
KALV is currently included in the following stock indexes tracked on ChartMill.
KALV Financial Highlights
Over the last trailing twelve months KALV reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 47.72% compared to the year before.
Income Statements
Revenue(TTM)64.20M
Net Income(TTM)-109.67M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.26% | ||
| ROE | -645.16% | ||
| Debt/Equity | 15.81 |
Chartmill High Growth Momentum
EPS Q2Q%-1.1%
Sales Q2Q%N/A
EPS 1Y (TTM)47.72%
Revenue 1Y (TTM)4401.82%
KALV Ownership
Ownership
Inst Owners125.72%
Shares51.22M
Float44.95M
Ins Owners1.69%
Short Float %43.7%
Short Ratio18.82
KALV Industry Overview
KALV operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
KALV Latest News, Press Relases and Analysis
KALV Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KALV
Company Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Framingham, Massachusetts and currently employs 270 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Company Info
IPO: 2015-04-09
KALVISTA PHARMACEUTICALS INC
200 Crossing Boulevard
Framingham MASSACHUSETTS 02142 US
CEO: T. Andrew Crockett
Employees: 275
Phone: 18579990075
KALVISTA PHARMACEUTICALS INC / KALV FAQ
Can you describe the business of KALVISTA PHARMACEUTICALS INC?
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Framingham, Massachusetts and currently employs 270 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
What is the current price of KALV stock?
The current stock price of KALV is 26.67 USD. The price increased by 38.62% in the last trading session.
What is the dividend status of KALVISTA PHARMACEUTICALS INC?
KALV does not pay a dividend.
How is the ChartMill rating for KALVISTA PHARMACEUTICALS INC?
KALV has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is KALV stock listed?
KALV stock is listed on the Nasdaq exchange.
Is KALVISTA PHARMACEUTICALS INC (KALV) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KALV.
Can you provide the market cap for KALVISTA PHARMACEUTICALS INC?
KALVISTA PHARMACEUTICALS INC (KALV) has a market capitalization of 1.37B USD. This makes KALV a Small Cap stock.